News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OxThera, Inc. Coordinates FP7 Project, Elimox - €2.19 Million Provided for Drug Development in Hyperoxaluria


9/24/2013 9:46:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM, September 24, 2013 /PRNewswire/ --

OxThera AB announces today that it is the coordinator of a new EU-project, Elimox, that will run for 2 years and has been provided an FP7 grant of €2.19 million. The primary aim of the project is to develop an innovative and unique bacterial pharmaceutical product for the treatment of a severe and debilitating inherited disease; Primary Hyperoxaluria (PH).

"We are extremely happy to get this contribution for the development of a treatment for Primary Hyperoxaluria," says Elisabeth Lindner, Coordinator for the Elimox project and CEO of OxThera, "The research findings from this project will add profound knowledge relating to the impact of probiotic pharmaceutical treatments and its subsequent role in health and disease," Elisabeth Lindner continues.

The Elimox project will perform bacterial drug development, analytical methods development and clinical development for PH. The bacteria, Oxalobacter formigenes, has been shown to actively promote enteric elimination of oxalate in animal models (Hatch, 2011 and 2013). Early exploratory clinical studies evaluating an initial formulation of the bacteria showed a substantial decrease in urinary oxalate excretion in subjects with PH (Hoppe, 2006).

About Elimox

The Elimox project is funded as part of the program "Research for the benefit of specific groups, Research for SMEs". The consortium includes 12 partners; OxThera AB, Sweden, Cobra Biologics Ltd, UK, SymbioPharm GmbH, Germany, Ergomed Clinical Research Ltd, UK, Universitätsklinikum Bonn, Germany, Hospices Civils de Lyon, France, University College London Hospitals NHS Foundation Trust, UK, Galenica AB, Sweden, K.A.B.S. Laboratories Inc., Canada, Medizinisches Versorgumszentrum Institute für Microökologie, Germany, TNO, Netherlands and Bio-Images Research Ltd, UK.

About Primary Hyperoxaluria

Primary Hyperoxaluria is a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. There is a high unmet medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES